Cytori Therapeutics announced it has received approval from Singapore’s Health Sciences Authority (HSA) for the Celution System for autologous re-implantation or reinfusion of a patient’s own adipose-derived regenerative cells (ADRCs). The system allows access to a patient’s own ADRCs at the point-of-care for various injuries and conditions.
“Celution System approval and claims in Singapore complements our existing Asia-Pacific approvals by strengthening market access in the region and reinforcing our global regulatory strategy,” said Seijiro Shirahama, Asia-Pacific president for Cytori. “We anticipate seeing a relevant impact on sales in 2014 as a result of the approval in Singapore, combined with recent approvals and registrations in Australia, New Zealand and in Japan.”
Asia-Pacific has been an important region for Cytori and continues to be, supported by an increasing number of regulatory approvals and issued patents. Cytori received patents in Singapore in 2007 and 2008 covering the Celution System and for vascular conditions relating to the use of ADRCs to restore blood flow.
A major medical market, Singapore is a medical innovation and research leader that ranked fourth in global healthcare infrastructure in the 2010 IMD World Competitiveness Yearbook. Singapore has devoted more than $12 billion in ongoing support for research, innovation and enterprise activities between 2011 and 2015, with $2.9 billion dedicated to the biomedical space.
For more information about Cytori Therapeutics, visit www.cytori.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
